Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||DM-CHOC-PEN||Phase I||Actionable||In a Phase I trial, DM-CHOC-PEN (4-Demethyl-4-cholesteryloxycarbonylpenclomedine) treatment resulted in complete/partial response in 25% (3/12) of adolescent and young adult patients with advanced solid tumors (non-small cell lung cancer, acute lymphocytic leukemia, astrocytoma), improved quality of life, progression-free survival, and overall survival of 8-26 months (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A086; NCT02889445).||detail...|
|PubMed Id||Reference Title||Details|
|Early clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in adolescents and young adults (AYA) with cancers||Full reference...|